Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Study of Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer After Platinum-Based Therapy

NCT00095199 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00095199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00095199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Study of Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer After Platinum-Based Therapy
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2005
Completion date
July 31, 2011
Enrollment
939 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer